Key Highlights

● Illumina rallied hard, ranking among the S&P 500's stronger performers, as part of a broad life-science tools rally.

● Charles River, Thermo Fisher and Danaher all rose alongside it.

● Genomics peer PacBio surged on a new rare-disease data partnership.

Illumina climbed sharply on Monday, Oct. 5, leading genomics and life-science tools stocks higher as part of a broad group rally.

A big move across the group

Illumina (NASDAQ:ILMN) rallied hard on Monday, according to market data, ranking among the stronger performers in the S&P 500.

Life-science tools stocks rallied as a group. Charles River Laboratories (NYSE:CRL) climbed sharply to a 52-week high of $303.33 and was the S&P 500's second-best performer, while Thermo Fisher Scientific (NYSE:TMO) and Danaher (NYSE:DHR) also rose.

Genomics joins in

Other genomics and health-data names moved higher too. PacBio (NASDAQ:PACB), a smaller DNA-sequencing company, surged after EpiSign and Geneyx Genomex announced a Partnership to combine genomic and epigenomic analysis for rare diseases using PacBio's HiFi sequencing data. Tempus AI (NASDAQ:TEM), which works with genomic and clinical data, also rallied.

Illumina is the best-known name in DNA sequencing. Its machines and chemistry are used by research labs, hospitals and drug developers to read genetic code, from cancer testing to rare-disease diagnosis and population studies. Because it sells into research budgets, its shares often move with the broader tools group.

Health care was split

The gains for tools and genomics stood out in a weak sector. Health care was the softest group in the S&P 500 at midday and posted a modest decline by the close.

Big drugmakers dragged. Merck (NYSE:MRK) was the worst stock in the Dow, Bristol-Myers Squibb (NYSE:BMY) slid after a downgrade from Leerink Partners, and Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) also fell. In contrast, Vaccine stocks were busy: Vaxcyte (NASDAQ:PCVX) soared on Phase 3 data for its VAX-31 pneumococcal vaccine, and Moderna (NASDAQ:MRNA) rallied ahead of joining the Nasdaq-100.

Records for the Nasdaq

The wider market finished higher. The Nasdaq Composite rose 286.45 points to a record close of 27,477.31, and the Nasdaq-100 set a record at 31,076.44. The S&P 500 gained 51.23 points to 7,773.95, just shy of its summer record, and the Dow Jones Industrial Average added 90.94 points to 51,267.90.

Growth stocks shrugged off rising bond yields. The 10-year Treasury Yield rose to its highest close since 2002, and the ISM services survey showed prices paid at their highest since July 2022. Still, Friday's jobs report, with just 29,000 positions added in September, cut the odds of another Fed rate hike in October to roughly one in four or less, down from better than even a week earlier.

Daniela Hathorn of Capital.com explained the tension: "growth stocks are rallying because Fed expectations have softened, while the Risk-Free Rate against which those valuations are judged remains exceptionally high."

Oil eased, with Brent settling at $100.32 a barrel, after G7 nations agreed to release 100 million barrels of crude and diesel from emergency reserves.

Mega-cap AI stocks carried much of the load. Nvidia (NASDAQ:NVDA) closed at a record, with a Market Value of about $5.7 trillion, and Microsoft (NASDAQ:MSFT) climbed after an upgrade from Melius Research. Breadth on the Nasdaq was narrow, even as the index hit a new high.

What to watch

For Illumina, the next major checkpoint is its quarterly Earnings report, where investors will want updates on Demand for sequencing instruments and consumables.

For the broader market, minutes of the Fed's September meeting are due on Wednesday, Oct. 7, at 2 p.m. ET. PepsiCo reports Thursday, Delta Air Lines Friday, and bank earnings start on Oct. 13. The Fed's next policy meeting is Oct. 27–28.